Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib
Proceedings of the National Academy of Sciences · 05.08.2025 · 122 (31)
DOI: 10.1073/pnas.2509012122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 30.07.2025. Verfasst von Lorenzo Maso und 6 weiteren Autor:innen. Beteiligte Einrichtung: Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Antigens, Neoplasm. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute (NCI).
Abstract (Originalsprache)
Effective immune therapy against cancer ideally should target a cancer-specific antigen, an antigen that is present exclusively in cancer cells. However, there is a paucity of cancer-specific antigens that are endogenously produced. HapImmune™ technology utilizes covalent inhibitors directed to an intracellular cancer driver to create cancer-specific neoantigens in the form of drug–peptide conjugates presented by class I MHC molecules. Our previous study with sotorasib, an FDA-approved covalent inhibitor of KRAS(G12C), demonstrated that drug-treated cells produce such neoantigens and can be killed by T cell engagers directed against the drug–peptide/MHC complex. Thus, this technology can unite targeted and immune therapies. In the present study, we examined whether this approach could generalize to another FDA-approved KRAS(G12C) inhibitor, adagrasib, whose chemical structure and cysteine reactivity differ substantially from sotorasib. We developed antibodies selective to adagrasib-KRAS(G12C) peptides presented by HLA-A*03 and A*11 that also show cross-reactivity to other KRAS(G12C) inhibitors presented in the same manner. Cryoelectron microscopy structures revealed a mode of adagrasib-peptide/HLA recognition distinctly different from that of sotorasib-directed HapImmune antibodies. The antibodies in a bispecific T cell engager format killed adagrasib-resistant lung cancer cells upon adagrasib treatment. These results support the broad applicability of the HapImmune approach for creating actionable cancer-specific neoantigens and offer candidates for therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Perlmutter Cancer Center, New York University Langone Health, New York, NY 10016.
- Aethon Therapeutics, Long Island City, NY 11101.
- Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016.
- Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016.
ORCID-Profile: Lorenzo Maso, Epsa Rajak, Takamitsu Hattori, Benjamin G Neel, Shohei Koide
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute (NCI)
Zitieren
APA
Maso, L., Rajak, E., Hattori, T., Hu, Z., Koide, A., Neel, B. G., & Koide, S. (2025). Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib. Proceedings of the National Academy of Sciences, 122(31). https://doi.org/10.1073/pnas.2509012122
Vancouver
Maso L, Rajak E, Hattori T, Hu Z, Koide A, Neel BG, et al. Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib. Proceedings of the National Academy of Sciences. 2025;122(31). doi:10.1073/pnas.2509012122
BibTeX
@article{Maso2025,
author = {Maso, Lorenzo and Rajak, Epsa and Hattori, Takamitsu and Hu, Zhengshan and Koide, Akiko and Neel, Benjamin G and Koide, Shohei},
title = {Generation of actionable, cancer-specific neoantigens from KRAS(G12C) with adagrasib},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {31},
doi = {10.1073/pnas.2509012122}
}
EUVIMED